Table 1 Patient and Tumor Characteristics
|  | Total (n = 113) N (%) | TX (n = 54) N (%) | TE (n = 59) N (%) | p |
|---|---|---|---|---|
Age | ||||
   > 50 | 58 (51.3) | 33 (61.1) | 25 (42.4) | 0.072 |
   ≤ 50 | 55 (48.7) | 21 (38.9) | 34 (57.6) |  |
Histological Type | ||||
  No special type | 99 (87.6) | 47 (87.0) | 52 (88.1) | 0.853 |
  Invasive lobular | 7 (6.2) | 4 (7.4) | 3 (5.1) |  |
  Mixed | 7 (6.2) | 3 (5.6) | 4 (6.8) |  |
Initial cT Stage | ||||
  cT0 | 1 (0.9) | 0 (0.0) | 1 (1.7) | 0.704 |
  cT1 | 23 (20.4) | 9 (16.6) | 14 (23.7) |  |
  cT2 | 70 (61.9) | 36 (66.7) | 34 (57.6) |  |
  cT3 | 9 (8.0) | 5 (9.3) | 4 (6.8) |  |
  cT4 | 10 (8.8) | 4 (7.4) | 6(10.0) |  |
Initial cN Stage | ||||
  N0 | 12 (10.6) | 7 (13.0) | 5 (8.5) | 0.730 |
  N1 | 46 (40.7) | 23 (42.6) | 23 (39.0) |  |
  N2 | 44 (38.9) | 20 (37.0) | 24 (40.7) |  |
  N3 | 11 (9.7) | 4 (7.4) | 7 (11.9) |  |
Hormone Receptor | ||||
  Negative | 35 (31.0) | 15 (27.8) | 20 (33.9) | 0.618 |
  Positive | 78 (69.0) | 39 (72.2) | 39 (66.1) |  |
  Ki-67 |  |  |  |  |
   > 20% | 72 (63.7) | 33 (61.1) | 39 (66.1) | 0.722 |
   ≤ 20% | 41 (36.3) | 21 (38.9) | 20 (33.9) |  |
Breast Surgery | ||||
  Breast conservation | 22 (19.5) | 11 (20.4) | 11 (18.6) | 1.000 |
  Mastectomy | 91 (80.5) | 43 (79.6) | 48 (81.4) |  |
  Adjuvant Chemotherapy | 95 (84.1) | 48 (92.6) | 47 (83.1) | 0.181 |
  Original neoadjuvant regimen | 64 (64.5) | 23 (47.9) | 41 (87.2) |  |
Non-cross resistant regimen | ||||
  Anthracycline + CTX | 17 (17.1) | 17 (35.4) | 0 (0) |  |
  Capecitabine alone | 6 (6.1) | 1 (2.1) | 5 (10.6) |  |
  Others | 8 (8.1) | 7 (14.6) | 1 (2.1) |  |
Adjuvant Radiotherapy | ||||
  Yes | 109 (96.4) | 52 (96.3) | 54 (91.5) | 0.441 |
  No | 4 (3.6) | 2 (3.7) | 5 (8.5) |  |
Adjuvant Endocrine Therapy | 76 (67.3) | 37 (68.5) | 39 (66.1) | 0.784 |
  TAM | 19 (16.8) | 9 (16.7) | 10 (17.0) |  |
  AI | 48 (42.5) | 25 (46.3) | 23 (39.0) |  |
  OFS + TAM / AI | 9 (8.0) | 3 (5.6) | 6 (10.1) |  |